A New Test Could Save Arthritis Patients Time, Money, and Pain. Will It Be Used?
SAN DIEGO-- Erinn Maury understood Remicade wasn't the ideal drug for Patti Schulte, a rheumatoid arthritis client the doctor saw at her Millersville, Maryland, practice. Schulte's inflamed, uncomfortable joints had not reacted to Enbrel or Humira, 2 drugs in the very same class.
The insurance provider firmly insisted, so Schulte went on Remicade. It didn't work either.
What's more, Schulte suffered a serious allergy to the infusion treatment, needing a heavy dosage of prednisone, a steroid with serious adverse effects if utilized at high dosages for too long.
After 18 months, her insurance provider lastly authorized Maury's drug of option, Orencia. Already, Schulte's vertebrae, deteriorated by prednisone, had actually begun splitting. She was just 60.
Schulte's story of di...